Korean J Ophthalmol.  2020 Oct;34(5):347-352. 10.3341/kjo.2019.0129.

Effect of Prostaglandin Analogues on Central Corneal Thickness: 3-Year Follow-up Results

• Jang M
• Kang KE
• Cho BJ

• KMID: 2507384
• DOI: http://doi.org/10.3341/kjo.2019.0129

Abstract

Purpose
To evaluate the effects of each subgroup of prostaglandin analogues (PGAs) on central corneal thickness (CCT) in patients with normal tension glaucoma (NTG).
Methods
We retrospectively reviewed 55 eyes of 55 patients with NTG who were receiving PGA therapy. Patients who were treated with 0.005% latanoprost (16 eyes), 0.0015% tafluprost (16 eyes), or 0.004% travoprost (23 eyes) monotherapy were included. CCT assessments were performed at baseline and 1, 2, and 3 years after initiation of treatment.
Results
In the NTG group, the mean CCT showed a decreasing trend, and there was a significant difference in mean CCT at 1, 2, and 3 years compared with baseline (baseline, 538.16 ± 32.14; 1 year, 526.55 ± 37.30 µm [p = 0.00]; 2 years, 521.67 ± 36.79 µm [p = 0.00]; 3 years, 520.43 ± 36.88 µm [p = 0.00]). The reduction of CCT was confirmed by subgroup analysis. In the 0.005% latanoprost group, mean CCT was decreased at 1 year (p = 0.11), 2 years (p = 0.00), and 3 years (p = 0.02). In the 0.0015% ta-fluprost group and the 0.004% travoprost group, mean CCT was also significantly decreased at all years (p = 0.00). No statisti-cal difference was observed between the NTG subgroups (p = 0.06).
Conclusions
Topical therapy with PGAs appeared to cause a significant decrease in CCT reduction in patients with NTG. A long-term follow-up study including more participants is needed.

Keyword

Central corneal thickness; Low tension glaucoma; Prostaglandin analogue